TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03724708

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IUD
Description: IUD insertion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IUD
Description: IUD insertion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IUD
Description: IUD insertion
Study: NCT04265612

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pico® negative pressure dressing
Description: Pico® negative pressure dressing that will be placed in the operating room in both sternal wound and saphenectomy.The dressing will remain on for 7 days without waking up, unless it is saturated, in which case only the dressing will be changed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aquacel Surgical® hydrogel dressing
Description: Aquacel Surgical® hydrogel dressing that will be placed in the operating room in both sternal wound and saphenectomy. This dressing will remain in place for 7 days without getting up, unless it has become saturated, in which case, only the dressing will be changed.
Study: NCT02450253

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: single dose, 20 mg capsule p.o.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose, matching capsule p.o.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive functioning tests
Description: Cognitive function tests will be performed prior to MRI scan 1 performed prior to IMP dosing on 2 occasions as patient will act as their own control

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive functioning tests
Description: Cognitive function tests will be performed prior to MRI scan 1 performed prior to IMP dosing on 2 occasions as patient will act as their own control

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neuropsychological tests
Description: Neuropsychological tests will be performed prior to pre IMP dose MRI scan \& then parallel V2 of the tests repeated 3-5 post IMP dose and before 2nd MRI scan.~Participants act as own controls as 1 IMP occasion will be placebo- 2nd IMP occasion will be active. 7-30 days apart

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Neuropsychological tests
Description: Neuropsychological tests will be performed prior to pre IMP dose MRI scan \& then parallel V2 of the tests repeated 3-5 post IMP dose and before 2nd MRI scan.~Participants act as own controls as 1 IMP occasion will be placebo- 2nd IMP occasion will be active. 7-30 days apart

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI Scan - Arterial Spin Labelling
Description: Pre and post IMP dose on 2 occasions to detect difference in blood flow in deep brain 4 MRI scans in total

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MRI Scan - Arterial Spin Labelling
Description: Pre and post IMP dose on 2 occasions to detect difference in blood flow in deep brain 4 MRI scans in total
Study: NCT02362373

Intervention type: DRUG
Group type: OTHER
Intervention: levonorgestrel IUS
Description: placement of levonorgestrel intrauterine system
Study: NCT00064701

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus Modified Release (MR)
Description: The target range for whole blood tacrolimus trough concentrations was 7 to 16 ng/mL for days 0 through 90, and 5 to 15 ng/mL thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: The target range for whole blood tacrolimus trough concentrations was the recommended trough concentration range for Prograf: 7 to 16 ng/mL for days 0 through 90 and 5 to 15 ng/mL thereafter.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine microemulsion
Description: The target range for whole blood cyclosporine trough concentrations was 125 to 400 ng/mL for days 0 through 90, and 100 to 300 ng/mL thereafter.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: Oral
Study: NCT00002676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study: NCT04696770

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Mindfulness techniques will be taught to the participants
Study: NCT01804335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD5789 0.01% Cream
Description: CD5789 0.01% cream applied on the lesions once daily for twelve weeks.
Study: NCT00002676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET cobalt-60 gamma ray therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy
Study: NCT01462513

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: L-BLP25
Description: Treatment: 930µg per treatment once weekly for 8 weeks, then at 6-week intervals during years 1 and 2.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment: Placebo 930µg per treatment, once weekly for 8 weeks, then at 6-week intervals during years 1 and 2.
Study: NCT00763893

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study (e.g., comparison of different dosages of drug) and/or among similar interventions (e.g., comparison of multiple implantable cardiac defibrillators). For example, interventions involving drugs may include dosage form, dosage, frequency and duration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: 50 mg/day if \< weight 50 kg 100 mg/day if weight \> 50 kg
Study: NCT02464631

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir + Ribavirin 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir + Ribavirin 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir + Ribavirin 3
Study: NCT01109381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GT08
Description: GT08 is the combination of omeprazole 40mg daily, lauric acid 150-300mg daily, NAC 1.2 - 2g daily
Study: NCT01968785

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Dose 25 Gy
Description: Renal Denervation is performed using the Beta-Cath 3.5F to a deliver radiation dose 25 Gy to the renal artery.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Dose 50 Gy
Description: Renal Denervation is performed using the Beta-Cath 3.5F to a deliver radiation dose 50 Gy to the renal artery.
Study: NCT03461861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGB101 220 mg
Description: AGB101 oral dose of 220 mg/day capsule, given as once-daily dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGB101 220 mg
Description: AGB101 oral dose of 220 mg/day capsule, given as once-daily dosing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, oral capsule given once-daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, oral capsule given once-daily.
Study: NCT01765881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: administration of Misoprostol 25 micrograms capsule by intravaginal route every 4 hours, up to 4 capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinoprostone
Description: administration of one sustained released pessary of 10 milligrams by intravaginal route
Study: NCT01405079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib 250 mg/day oral daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine+Cisplatin
Description: Vinorelbine 25 mg/m2 intravenous infusion on day 1 and day 8, Cisplatin 75 mg/m2 on day 1 for 4 cycles
Study: NCT01946009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cidofovir 1% cream's basis, 2gr, three times per week, during 4 weeks.
Study: NCT04509063

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Information about hypothetical mammography screening without benefits
Description: We will present an online questionnaire with two types of information on the harms of screening. Then we will compare the prevalence of irrational decisions in the two arms.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Information about hypothetical mammography screening without benefits
Description: We will present an online questionnaire with two types of information on the harms of screening. Then we will compare the prevalence of irrational decisions in the two arms.
Study: NCT00387686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhBMP-2/CPM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhBMP-2/CPM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhBMP-2/CPM

Intervention type: DRUG
Group type: OTHER
Intervention: rhBMP-2/CPM
Study: NCT04022954

Intervention type: DEVICE
Intervention: Catheter ablation
Description: Inquiry AFocusII Double Loop and Advisor HD Grid, Sensor Enabled

Intervention type: DEVICE
Intervention: Catheter ablation
Description: Inquiry AFocusII Double Loop and Advisor HD Grid, Sensor Enabled
Study: NCT02013154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01 150 mg
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01 150 mg
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01 300 mg
Description: Administered by IV infusion
Study: NCT00046566

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy protein-milk protein-carbohydrate
Description: 40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks, and 40 grams of carbohydrate per day for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk protein-carbohydrate-soy protein
Description: 40 grams of milk protein per day for 8 weeks, 40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Carbohydrate-soy protein-milk protein
Description: 40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks,
Study: NCT02013154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01 300 mg
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01 300 mg
Description: Administered by IV infusion
Study: NCT01861951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Study: NCT03826914

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CardioFlex Q10
Description: CardioFlex Q10 is a cardiovascular health supplement developed to increase collagen production, repair connective tissues, and help the body metabolize fats and protein. CardioFlex Q10 contains high amounts of lysine, proline and vitamin C, which the body requires to produce connective tissue (collagen). CardioFlex Q10 also includes additional supporting nutrients such as vitamin E, selenium, bio flavonoids, Coenzyme Q10 (Ubiqionol) and magnesium. The ingredients in CardioFlex Q10 help regulate the body's production of cholesterol, strengthen the arteries and heart, and reverse oxidation.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Isocaloric maltodextrin placebo that looks and tastes identical to CardioFLex Q10
Study: NCT01588080

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurally Adjusted Ventilatory Assist (NAVA)
Description: Neurally adjusted ventilatory assist (NAVA), an adjunct that can only be used with the Servo-i ventilator, allows the patient to synchronize spontaneous respiratory effort with mechanical ventilation. NAVA uses the electromyographic signal of the diaphragm (Edi) to transmit this electrical activity back to the ventilator. The NAVA catheter is a functional gastric tube that has electrodes embedded within it and positioned at the level of diaphragm using an electrocardiogram signal. These electrodes continuously (every 5ms) detect the amplitude, duration, and frequency of the Edi and provide pressure support in proportion to this electrical activity. Proportionality is controlled by a NAVA factor (cmH20/microvolt) and is adjusted by the user.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: SiPAP - placebo
Description: The Infant Flow® SiPAP provides noninvasive support to neonates. CPAP and Biphasic modes are provided by the Infant Flow® SiPAP. CPAP is an elevated pressure (above atmospheric) and is used to increase a premature babies functional residual capacity (FRC). CPAP is a modality used for babies with both central apneas and mild/moderate increase work of breathing. CPAP increases the FRC and ultimately recruits collapsed alveoli and improves gas exchange in the lungs. BiPhasic, on the other hand, is a modality used for babies that require more respiratory support than CPAP can provide. In BiPhasic mode, respiratory rate (RR), inspiratory time (Ti), and peak inspiratory pressures (PIP) are set and not synchronized with the patients breathing efforts.
Study: NCT02268318

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 2-Fermented dairy Product with No Phytosterols (control)
Description: 2-1 bottle of control product/day
Study: NCT01936129

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copaxone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (buffered normal saline w/v)
Study: NCT04252378

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Serratus Anterior Plane Block
Description: Deep Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Superficial Serratus Anterior Plane Block
Description: Superficial Serratus Anterior Plane Block was performed just before the start of surgery after anesthetic induction through ultrasound-guidance.
Study: NCT03260023

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TG4001
Description: PhIb: Dose escalation PhII: Established RP2D for TG4001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Anti PD-L1
Study: NCT03147768

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Distal Pancreatectomy Sealing Using LTW
Description: The device's intended use is to seal the pancreatic surface using a laser to weld human albumin based biomaterials after surgical removal of pancreatic tumors during a partial pancreatectomy.
Study: NCT03748381

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: During cataract surgery patients will be implanted with the AT Zeiss Lisa tri in one eye and the Rayner trifocal in the contralateral eye
Study: NCT04437303

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuation of oral anticoagulants
Description: Oral anticoagulant treatment will not be interrupted before the procedure.
Study: NCT03260023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Anti PD-L1
Study: NCT03004846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2981278 ointment
Description: GSK2981278 ointment will be applied topically twice daily for 8 weeks to all subjects in Part A and to randomized subjects in Part B. GSK2981278 will be a white to off-white ointment and a thin layer will be applied to all affected areas for given timeframe.~GSK2981278 is available as white to off-white ointment in unit strength 4% (w/w), 2% (w/w) and 0.8% (w/w), for topical application for application as thin layer to all affected areas .
Study: NCT04437303

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interruption of oral anticoagulants
Description: Peri-operative interruption of oral anticoagulants will be according to the Dutch guideline on antithrombotic therapy.~* For direct oral anticoagulant users this will be in general 48 hours before the procedure, except for Dabigatran users with renal insufficiency: with estimated glomerular filtration rate 50-80 mL/min/1.73m\^2 72 hours and with estimated glomerular filtration rate 30-50 mL/min/1.73m\^2 96 hours before procedure.~* For vitamin K antagonist users this will be 5 days for phenprocoumon and 3 days for acenocoumarol.~* After the procedure oral anticoagulants will be resumed after 24 hours, if deemed safe by the treating physician.
Study: NCT03413839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapeutic Scoliosis Specific Exercises (PSSE)
Description: Exercises with emphasis on trunk extensor strengthening, and teaching patient better postural strategies in supine, sidelying, sitting, standing, and dynamic movements (walking, squatting), led by a PSSE-trained physical therapist.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Conventional Physical Therapy (PT)
Description: Conventional PT includes generalized pelvis, and trunk strengthening, lower extremity (LE) stretching, and use of modalities (ice and heat), iontophoresis and E-Stim.
Study: NCT03868891

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMST150
Description: The EMST150 consists of a handheld plastic tube with a mouthpiece on one end and an adjustable valve on the other end. Your child will close his/her lips around the mouthpiece and breathe out against resistance. The EMST150 will be adjusted to the point where airflow stops. Each day, your child will blow into the EMST150 5 sets of 5 times with a 10-15 second rest between each use and a 1-2 minute rest between each set of 5. You will adjust the resistance of the device each week, take a picture of the device settings, and document exercise sets performed in an exercise diary. These exercises will be performed twice in each nostril 2 times a day until your child's next visit at the MEPL (at least 8 weeks). Each session should take approximately 10-15 minutes, for a total of 30 minutes per day.
Study: NCT02257658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycyline

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Incentive
Study: NCT01160796

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1x14-day course of treatment during 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lcr35®
Description: 1x14-day course of treatment during 4 cycles
Study: NCT03253510

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Poly-amide
Description: New denture base material that exhibit high flexibility, physical strength, heat and chemical resistance and the exceedingly rare allergy response

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Poly-methyl methacrylate
Description: Gold standard denture base material
Study: NCT00682500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calfactant
Description: Intratracheal Instillation of 0.5 mL/cm of height of 60 mg/mL suspension in two aliquots at study entry. Repeat dosing 12 hours later if criteria are met.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Room Air (placebo)
Description: Administration of 0.5 ml/cm height of air at study entry into the trachea. Repeat dosing at 12 hours if criteria are met
Study: NCT02157623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levulan
Description: Levulan application followed by Red or Blue light PDT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red Light PDT
Description: Aktilite™ (red lamp) after Levulan application on lesions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blue Light PDT
Description: Blu-U® (blue lamp) after Levulan application on lesions
Study: NCT04129346

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fit2ThriveMB App
Description: The Fit2thriveMB app will encourage participants to increase their physical activity. Participants will be provided with educational information on physical activity and effective behavior change strategies for incorporating more physical activity into their daily lives to increase their step count. Participants will be prompted each morning to report the intensity of their symptom burden (0 to 10). Based on their symptom rating and their previous day's step counts, participants will be provided with three different options or levels of goals for that day to either increase or decrease 10-20% or remain constant.
Study: NCT04129346

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: The Fitbit measures PA intensity, steps, and heart rate and syncs directly with the smartphone and will automatically sync with the Fit2ThriveMB app and provide Fitbit data to the study team in real-time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Coaching Calls
Description: Participants will receive weekly coaching calls which will: a) provide feedback on the previous week's symptom burden and progress on PA goals; b) review personalized goals and strategies for increasing PA for the next week; c) provide instruction on effective behavioral change techniques
Study: NCT00684268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silibinin
Description: comparison of different dosing schedule of Silibinin infusions (20 mg/kg/d infused over 2 hours) A: 3x5days B: 14 days C: 21 days D: 28 days~sequential the infusion duration will be shortened - 2 hours, then 1 hr and then 1/2 hr/infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silibinin
Description: 20 mg/kg Silibinin iv /d /21 days, antiviral combination therapy will be continued